? RECRUITMENT, INTERVENTION AND SURVEY SHARED RESOURCE (RISSR) The RISSR was established in 2003, as the Behavioral Measurement Shared Resource (BMSR), to provide a mechanism for supporting behavioral, epidemiological and clinical research within the broader research goals of the OSUCCC. Renamed in 2019, the RISSR provides essential services to support non-interventional studies (observational, epidemiologic) as well as non-therapeutic intervention studies. Thus, the RISSR is a niche service for population scientists in CC and MCC providing efficient and high quality services for investigators to conduct population science research. RISSR also works with the BSSR to support the Total Cancer Care (TCC) project accruals, and translational research involving human data collection and interventions for all 5 research programs. For the next funding period, the RISSR specific aims are to: 1) provide expertise in research design, the selection and/or development of surveys and study measures, including patient-reported outcomes; 2) assist investigators with participant recruitment, accrual goals, and retention to ensure the inclusion of research participants that are representative of the target population(s); and 3) provide investigators with expertise and services in the collection and management of quantitative and qualitative research data, and population-based data retrieval for grant applications and registry studies. Collected data are managed for seamless transfer to the BSR for data analysis. Over the current funding cycle, the major changes to the RISSR were greater adoption of electronic data collection for the majority of OSUCCC studies, using text messaging with participants for more flexible communication, data collection and study conduct; increased use of mobile health interventions; and providing support for more program projects and large multi-heath center/ multi-state research projects. During the current funding cycle, RISSR has supported 35 principal investigators (54% OSUCCC members) and contributed to 71 publications (1 >10 impact factor) and 9 NCI grants including 1 K01, 1 K07, 1 K12, 1 P01, 2 P50s, 2 R01s, and 1 R37. The RISSR will directly support the OSUCCC priority for immune-oncology and cancer prevention and control. The RISSR will expand its staff, instrumentation and services before capacity is reached. In the next funding cycle, the RISSR will: 1) further develop and customize survey and data collection methods; 2) expand and support participant recruitment registries for rapid accrual for interventional and epidemiological studies; 3) expand the provision of smart phones to study participants to reduce disparities in participant recruitment and participation; and 4) develop greater linkages with the BISR to share computer platforms and expertise related to clinical informatics, eHealth interventions using the electronic health record, and health services research. The RISSR will also work with the BSR and BISR as part of the Biomedical Informatics Coordinating Center (BMICC) Working Group to establish national data coordinating centers at the OSUCCC on cancer-related topics. The annual budget of the RISSR is $1,631,722, yet the CCSG request is $92,102 (5.6%) reflecting strong institutional support and a robust chargeback system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090018
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Ghoussaini, Maya; Edwards, Stacey L; Michailidou, Kyriaki et al. (2018) Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 9:16193

Showing the most recent 10 out of 2602 publications